Therefore, more research is needed to understand the underlying mechanisms and to determine long-term safety and efficacy in humans
April 2026: As of April 1, 2026, there are 73 pending lawsuits in MDL 3163 IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation , which involves claims against Novo Nordisks Wegovy
Often worth exploring for Adults noticing age-related decline in recovery, sleep, or energy Active people who want a clinician-guided plan instead of self-directed use Patients who want their protocol built on labs, not guesswork People already dialing in nutrition, training, and sleep who want added support Who should avoid CJC-1295 and Ipamorelin
Entorhinal cortex-based metabolic profiling of chronic restraint stress mice model of depression
Mealtime insulin to cover the intake of carbohydrate and other macronutrients